Siemens Healthineers AG (SHL) Earnings Call Transcripts

Siemens Healthineers AG's Latest Earnings Call - Q2 FY2026

In Q2 of fiscal 2026, Siemens Healthineers AG reported a revenue of €4.2 billion, reflecting a 4.5% year-over-year growth, while adjusted earnings per share (EPS) was €0.55, up 16% from the previous year. The company updated its full-year revenue growth guidance to 4.5%-5% due to challenges in its Diagnostics segment, particularly in China, which is experiencing a structural market rebasing. Management signaled a cautious outlook for Diagnostics but expressed confidence in a recovery in the second half of the fiscal year.

Reported metrics

Guidance from management

Management updated its revenue growth outlook for fiscal 2026 to 4.5%-5%, primarily due to challenges in the Diagnostics segment. Adjusted EPS guidance was lowered to a range of €2.20 to €2.30.

What management said

And with regard to accounting treatment of the diagnostic business, I mean the rules are relatively clear. You can only account for business as discontinued operations if it is very certain that you will close something with the business and the business will, so say, leave your portfolio of businesses if and when it is very clear to get this done within 12 months. We are not at this point in time yet.

And Hader, maybe on that growth rate, I think when you think about 7% based on a 15% or something like growth in the year before, I think these are super tough comps. So I think it's -- as Bernd said, the market is very attractive. It's working very fine for us there, and we are very happy with what we see in the U.S. market. It's more a reflection of the very tough comps.

What analysts pressed on

Analysts expressed concerns regarding the structural challenges in the Diagnostics segment, particularly in China, and the potential impact on long-term growth. There were also questions about the inflationary pressures affecting margins and how the company plans to navigate these headwinds.

Main topics on the call

• Diagnostics Segment Challenges — The Diagnostics segment faced a significant revenue decline of 6% due to structural market rebasing in China. Management noted, "This quarter is a bit of a perfect storm in terms of the China headwinds peaking plus inten...
• Imaging and Precision Therapy Growth — Imaging and Precision Therapy segments showed strong underlying performance with a combined growth of 6.1%. CEO Montag stated, "The synergetic core of our portfolio with Imaging and Precision Therapy continues to show st...
• Leadership Changes — Siemens Healthineers announced a generational change in its leadership team to enhance focus on healthcare AI and operational efficiency. Montag emphasized, "We are strengthening our frontline leadership with top talent ...
• Updated Financial Guidance — The company revised its full-year guidance for adjusted EPS to a range of €2.20 to €2.30, down from €2.30, primarily due to inflationary pressures. CFO Schmitz stated, "The midpoint of our EPS range moves from formerly E...

Read the full Siemens Healthineers AG transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 51 Siemens Healthineers AG earnings call transcripts on record, spanning February 3, 2020 to July 31, 2026. Based on this history, Siemens Healthineers AG reports quarterly. The most recent call on file is dated July 31, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SHL

Exchange

XTRA

Country

DE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

51

First call

February 3, 2020

Most recent

July 31, 2026

Reporting cadence

quarterly